Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pang, Y.
Right arrow Articles by Marchase, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pang, Y.
Right arrow Articles by Marchase, R. B.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:1074-1081, 2004
© 2004 by the American Diabetes Association, Inc.

Hexosamine Pathway Is Responsible for Inhibition by Diabetes of Phenylephrine-Induced Inotropy

Yi Pang1, Pam Bounelis1, John C. Chatham2, and Richard B. Marchase1

1 Department of Cell Biology, University of Alabama at Birmingham, Birmingham, Alabama
2 Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama

Hyperglycemia diminishes positive inotropic responses to agonists that activate phospholipase C (PLC) and generate inositol trisphosphate (1,4,5). The mechanisms underlying both the inotropic responses and hyperglycemia’s effects on them remain undetermined, but data from isolated cardiomyocytes suggest the involvement of capacitative Ca2+ entry (CCE), the influx of Ca2+ through plasma membrane channels activated in response to depletion of endoplasmic or sarcoplasmic reticulum Ca2+ stores. In neonatal rat cardiomyocytes, hyperglycemia decreased CCE induced by PLC-mediated agonists. The attenuation of CCE was also seen with glucosamine, and the inhibition by hyperglycemia was prevented by azaserine, thereby implicating hexosamine biosynthesis as the responsible metabolic pathway. In the current study, the importance of hexosamine metabolites to hyperglycemia’s effects on inotropic responses was examined in isolated perfused rat hearts. The inhibition by hyperglycemia of phenylephrine-induced inotropy was reversed with azaserine and mimicked by glucosamine. An independent inhibitor of CCE, SKF96365, was also effective in blunting inotropy. These treatments did not inhibit inotropy induced by activation of adenylate cyclase through ß-adrenergic receptors. These data thus implicate CCE in responses to PLC-mediated agonists in the intact heart and point to the hexosamine pathway’s negative effect on CCE as being central to the inhibition seen with hyperglycemia.


Address correspondence and reprint requests to Richard B. Marchase, PhD, Department of Cell Biology, University of Alabama at Birmingham, 1530 3rd Ave. S., MCLM 690, Birmingham, AL 35294-0005. E-mail: marchase{at}uab.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Liu, R. B. Marchase, and J. C. Chatham
Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1391 - H1399.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. E. Zachara
The sweet nature of cardioprotection
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1324 - H1326.
[Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
N. Fulop, M. M. Mason, K. Dutta, P. Wang, A. J. Davidoff, R. B. Marchase, and J. C. Chatham
Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart
Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1370 - C1378.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
V. Champattanachai, R. B. Marchase, and J. C. Chatham
Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C178 - C187.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
T. Nagy, V. Champattanachai, R. B. Marchase, and J. C. Chatham
Glucosamine inhibits angiotensin II-induced cytoplasmic Ca2+ elevation in neonatal cardiomyocytes via protein-associated O-linked N-acetylglucosamine
Am J Physiol Cell Physiol, January 1, 2006; 290(1): C57 - C65.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Fauconnier, J. T. Lanner, S.-J. Zhang, P. Tavi, J. D. Bruton, A. Katz, and H. Westerblad
Insulin and Inositol 1,4,5-Trisphosphate Trigger Abnormal Cytosolic Ca2+ Transients and Reveal Mitochondrial Ca2+ Handling Defects in Cardiomyocytes of ob/ob Mice
Diabetes, August 1, 2005; 54(8): 2375 - 2381.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Hu, D. Belke, J. Suarez, E. Swanson, R. Clark, M. Hoshijima, and W. H. Dillmann
Adenovirus-Mediated Overexpression of O-GlcNAcase Improves Contractile Function in the Diabetic Heart
Circ. Res., May 13, 2005; 96(9): 1006 - 1013.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.